AcrobiosystemsLtd Past Earnings Performance
Past criteria checks 1/6
AcrobiosystemsLtd has been growing earnings at an average annual rate of 7.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 22.6% per year. AcrobiosystemsLtd's return on equity is 4.1%, and it has net margins of 18.3%.
Key information
7.6%
Earnings growth rate
-2.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 22.6% |
| Return on equity | 4.1% |
| Net Margin | 18.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think
Nov 06
AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear
May 02Recent updates
AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think
Nov 06Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%
Oct 01Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price
Jul 15AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear
May 02Revenue & Expenses Breakdown
How AcrobiosystemsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 595 | 109 | 302 | 150 |
| 30 Jun 24 | 575 | 119 | 287 | 140 |
| 31 Mar 24 | 553 | 139 | 272 | 130 |
| 31 Dec 23 | 544 | 154 | 255 | 122 |
| 30 Sep 23 | 534 | 166 | 242 | 119 |
| 30 Jun 23 | 514 | 186 | 227 | 123 |
| 31 Mar 23 | 497 | 195 | 204 | 120 |
| 01 Jan 23 | 474 | 204 | 186 | 112 |
| 30 Sep 22 | 461 | 219 | 169 | 107 |
| 30 Jun 22 | 438 | 211 | 146 | 84 |
| 31 Mar 22 | 410 | 187 | 131 | 70 |
| 01 Jan 22 | 385 | 174 | 117 | 60 |
| 30 Sep 21 | 351 | 159 | 87 | 49 |
| 30 Jun 21 | 322 | 146 | 73 | 44 |
| 31 Mar 21 | 286 | 135 | 64 | 37 |
| 31 Dec 20 | 246 | 116 | 57 | 31 |
| 31 Dec 19 | 103 | 11 | 57 | 20 |
| 31 Dec 18 | 70 | 11 | 34 | 17 |
| 31 Dec 17 | 47 | 7 | 25 | 10 |
Quality Earnings: 301080 has a high level of non-cash earnings.
Growing Profit Margin: 301080's current net profit margins (18.3%) are lower than last year (31.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301080's earnings have grown by 7.6% per year over the past 5 years.
Accelerating Growth: 301080's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301080 had negative earnings growth (-34.4%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Return on Equity
High ROE: 301080's Return on Equity (4.1%) is considered low.